I was doing a google search tonight trying to find information about switching from Tysabri to Ocrevus. I have been wondering if there are any issues going from immunosuppressent that operates on T-Cells to one that operates on B-Cells. I have no medical background so I don't have any idea if this can be an issue or not.
While doing my search I found the prescribing info for Ocrevus. Unlike the hype in the media, it has some facts from the studies about the incidence of cancer in the Ocrevus treated patients in the study. It also talks about the incidence of reactions to the first treatment despite the use of premedications. 30-40%!! Allen5280...looks like you have a lot of company with first dose reaction!
Here is the link for anyone interested in reading it:
If anyone runs into info about switching from Tysabri to Ocrevus, please post it or DM it to me. This decision is keeping me awake a night despite my neuro's enthusiasm.